靶向 PIM2 通过促进 CD8 T 细胞的效应功能和持久性增强抗肿瘤免疫
Targeting PIM2 improves antitumor immunity through promoting effector function and persistence of CD8 T cells.
PIM 激酶家族在肿瘤发生中起关键作用,但其在原代 T 细胞中的作用研究不足。
ALL SOURCES
Targeting PIM2 improves antitumor immunity through promoting effector function and persistence of CD8 T cells.
PIM 激酶家族在肿瘤发生中起关键作用,但其在原代 T 细胞中的作用研究不足。
SynNotch-iNOS CAR-macrophages remodel the tumor immune microenvironment and exhibit antitumor efficacy via a CD4(+) T cell-dependent mechanism.
本研究阐明了一种 CAR-M 的新型间接机制,将关注点从直接吞噬转向策略性的 TIME 重塑,为治疗实体瘤提供了基础。
Beyond Hematology-Current Insights into Chimeric Antigen Receptor (CAR) T-Cell Therapy for Skin and Connective Tissue Disorders.
嵌合抗原受体(CAR)T 细胞疗法是现代免疫治疗的一项重大进展。
Expression of VISTA regulated via IFN-γ governs endogenous T-cell function and exhibits correlation with the efficacy of CD19 CAR-T cell treated B-mal
我们的发现证实,内源性 T 细胞活化与功能受 VISTA 调控,VISTA 与 CAR-T 的治疗效果相关,并为 CAR-T 治疗中的复发患者提供了一种有前景的治疗策略。
Mapping variant effects on anti-tumor hallmarks of primary human T cells with base-editing screens.
关键 T 细胞基因中的单核苷酸变异(SNV)可驱动临床病理,并有望被重新利用以改善细胞癌症免疫治疗。
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid
这是第三代GD2靶向CAR-T细胞在转移性黑色素瘤及其他实体癌(如结直肠癌)患者中的首次报告,显示了可行性、安全性和免疫活性,但临床效果有限。
Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition.
嵌合抗原受体(CAR)T细胞在癌症治疗中显示出前景,但其作用机制尚不十分清楚。
Serpin B9 controls tumor cell killing by CAR T cells.
这些数据表明,serpin B9 是 CAR T 细胞介导的肿瘤细胞杀伤的耐药介质,应通过抑制或绕过它来改善 CAR T 细胞应答。
Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy.
多项研究已表明共生微生物对T细胞功能的影响,特别是在癌症检查点免疫治疗中。
Balancing activation and co-stimulation of CAR tunes signaling dynamics and enhances therapeutic potency.
靶向CD19的嵌合抗原受体(CAR)带有CD28和CD3信号域,已获美国FDA批准用于治疗B细胞恶性肿瘤。
MEMBER ACCOUNT
登录成功会直接打开下一页。